Abstract: Biomarkers that are indicative of efficacy of a treatment for rheumatoid arthritis or for the responsiveness to a treatment regimen in a subject being treated for rheumatoid arthritis are described. Also described are probes capable of detecting the biomarkers and related methods and kits for assessing, monitoring, and selecting treatment for rheumatoid arthritis.

Abstract: The present invention provides a cage particle distribution system for wastewater treatment comprising contactors. Said contactors include shells and the interior of said shells is a hollow cavity. At least one of the side walls, the upper surface and the lower surface of said shells are equipped with through-holes. Particles are loaded inside said shells and said particles can carry some microorganisms on their surfaces at least. Said cage systems are placed in the water of a wastewater system or a wastewater treatment system and one or multiple said cage systems can be placed. Separate aeration and/or liquid distribution into each individual cage system disperse particles in the system by the gas and/or liquid, which improves the efficiency of wastewater treatment.

Abstract: The present invention provides a cage particle distribution system for wastewater treatment comprising contactors. Said contactors include shells and the interior of said shells is a hollow cavity. At least one of the side walls, the upper surface and the lower surface of said shells are equipped with through-holes. Particles are loaded inside said shells and said particles can carry some microorganisms on their surfaces at least. Said cage systems are placed in the water of a wastewater system or a wastewater treatment system and one or multiple said cage systems can be placed. Separate aeration and/or liquid distribution into each individual cage system disperse particles in the system by the gas and/or liquid, which improves the efficiency of wastewater treatment.

Abstract: The present disclosure provides a light particle system or a mixed particle system for wastewater treatment comprising a contactor. The contactor includes a gas-liquid-solid three-phase region, and the gas-liquid-solid three-phase region includes gas phase, liquid phase, and solid phase. The liquid phase is a continuous phase and the solid phase is light particles or mixed particles. The mixed particles include light particles and heavy particles. The density of the light particles is lower than the density of the liquid phase and the density of the heavy particles is higher than the density of the liquid phase. The light particles or mixed particles are able to carry some microorganisms on their surfaces at least. The light/mixed particle-suspension system in the present invention applied in wastewater treatment can increase the concentration of microorganisms significantly, improve the ability to bear impact load, produce less sludge, and without sludge expansion.

Abstract: Resistin antagonists, including antibodies reactive with defined epitopes, are disclosed. Antigens useful for raising antibodies against human resistin are also disclosed. Methods of utilizing resistin antagonists to treat or alleviate the symptoms of the diseases with aberrant fibroblast activity including interstitial lung diseases, hypertrophic scarring, keloid scarring and scleroderma are also disclosed. Methods of utilizing resistin as a biomarker to diagnose the risk and/or progression of osteoarthritis are also disclosed. Further disclosed are methods of utilizing the antagonists to treat or alleviate the symptoms of osteoarthritis.

Abstract: A method for assessment of the suitability of a target therapy for a gastrointestinal-related disorder, such as ulcerative colitis, in a subject evaluates the presence, absence, and/or magnitude of expression of one or more genes in a 19- or 5-member gene panel in a sample. The method enables identification of the effectiveness of target therapies prior to starting a patient on such therapies.

Abstract: Resistin antagonists, including antibodies reactive with defined epitopes, are disclosed. Antigens useful for raising antibodies against human resistin are also disclosed. Methods of utilizing resistin antagonists to treat or alleviate the symptoms of the diseases with aberrant fibroblast activity including interstitial lung diseases, hypertrophic scarring, keloid scarring and scleroderma are also disclosed. Methods of utilizing resistin as a biomarker to diagnose the risk and/or progression of osteoarthritis are also disclosed. Further disclosed are methods of utilizing the antagonists to treat or alleviate the symptoms of osteoarthritis.

Abstract: Novel polypeptides (CNGH0010) and antibodies, including specified portions or variants, specific for at least one such CNGH0010 polypeptide, variant, or fragment thereof, as well as nucleic acids encoding such CNGH0010 polypeptides and antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, are useful for therapeutic and diagnostic formulations, administration and devices. The aforesaid polypeptides can be used to generate human, primate, rodent, mammalian, chimeric, humanized and/or CDR-grafted anti-CNGH0010 antibodies. The CNGH0010 polypeptides and antibodies are used in modulating or treating at least one CNGH0010-related disease in a cell, tissue, organ, animal, or patient.

Abstract: Novel polypeptides (CNGH0010) and antibodies, including specified portions or variants, specific for at least one such CNGH0010 polypeptide, variant, or fragment thereof, as well as nucleic acids encoding such CNGH0010 polypeptides and antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, are useful for therapeutic and diagnostic formulations, administration and devices. The aforesaid polypeptides can be used to generate human, primate, rodent, mammalian, chimeric, humanized and/or CDR-grafted anti-CNGH0010 antibodies. The CNGH0010 polypeptides and antibodies are used in modulating or treating at least one CNGH0010-related disease in a cell, tissue, organ, animal, or patient.

Abstract: Novel polypeptides (CNGH0010) and antibodies, including specified portions or variants, specific for at least one such CNGH0010 polypeptide, variant, or fragment thereof, as well as nucleic acids encoding such CNGH0010 polypeptides and antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, are useful for therapeutic and diagnostic formulations, administration and devices. The aforesaid polypeptides can be used to generate human, primate, rodent, mammalian, chimeric, humanized and/or CDR-grafted anti-CNGH0010 antibodies. The CNGH0010 polypeptides and antibodies are used in modulating or treating at least one CNGH0010-related disease in a cell, tissue, organ, animal, or patient.

Abstract: Novel polypeptides (CNGH0010) and antibodies, including specified portions or variants, specific for at least one such CNGH0010 polypeptide, variant, or fragment thereof, as well as nucleic acids encoding such CNGH0010 polypeptides and antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, are useful for therapeutic and diagnostic formulations, administration and devices. The aforesaid polypeptides can be used to generate human, primate, rodent, mammalian, chimeric, humanized and/or CDR-grafted anti-CNGH0010 antibodies. The CNGH0010 polypeptides and antibodies are used in modulating or treating at least one CNGH0010-related disease in a cell, tissue, organ, animal, or patient.

Abstract: Novel polypeptides (CNGH0010) and antibodies, including specified portions or variants, specific for at least one such CNGH0010 polypeptide, variant, or fragment thereof, as well as nucleic acids encoding such CNGH0010 polypeptides and antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, are useful for therapeutic and diagnostic formulations, administration and devices. The aforesaid polypeptides can be used to generate human, primate, rodent, mammalian, chimeric, humanized and/or CDR-grafted anti-CNGH0010 antibodies. The CNGH0010 polypeptides and antibodies are used in modulating or treating at least one CNGH0010-related disease in a cell, tissue, organ, animal, or patient.